Sirenia Capital Management LP Discloses New 7.2% Stake in Edesa Biotech, Inc.

On May 15, 2026, Sirenia Capital Management LP and Alex Silverstein filed a Schedule 13G regarding their holdings in Edesa Biotech, Inc. (EDSA). The filing reveals that the reporting persons have acquired a beneficial ownership of 600,000 common shares, representing 7.2% of the company's outstanding stock based on 8,348,161 shares as of February 12, 2026. This position is held through the SILV Fund, Ltd., an investment fund managed by Sirenia. Alex Silverstein, as the managing member of Sirenia's general partner, shares voting and dispositive power over these shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This initial filing marks a significant new position for the investment management firm in the Markham, Ontario-based biotechnology company. The principal business office for the reporting persons is located in Miami Beach, Florida.